DK1171111T3 - Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning - Google Patents

Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning

Info

Publication number
DK1171111T3
DK1171111T3 DK00917258T DK00917258T DK1171111T3 DK 1171111 T3 DK1171111 T3 DK 1171111T3 DK 00917258 T DK00917258 T DK 00917258T DK 00917258 T DK00917258 T DK 00917258T DK 1171111 T3 DK1171111 T3 DK 1171111T3
Authority
DK
Denmark
Prior art keywords
carnitine
high content
tablets
granules
alkanoyl
Prior art date
Application number
DK00917258T
Other languages
English (en)
Inventor
Ken Hassen
Original Assignee
Biosint S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosint S P A filed Critical Biosint S P A
Application granted granted Critical
Publication of DK1171111T3 publication Critical patent/DK1171111T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
DK00917258T 1999-03-26 2000-03-22 Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning DK1171111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000189A IT1305308B1 (it) 1999-03-26 1999-03-26 Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
PCT/IT2000/000097 WO2000057873A2 (en) 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine

Publications (1)

Publication Number Publication Date
DK1171111T3 true DK1171111T3 (da) 2003-08-25

Family

ID=11406608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00917258T DK1171111T3 (da) 1999-03-26 2000-03-22 Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning

Country Status (20)

Country Link
US (1) US6485741B2 (da)
EP (1) EP1171111B1 (da)
JP (2) JP4637367B2 (da)
KR (1) KR100729848B1 (da)
CN (1) CN1158072C (da)
AT (1) ATE238784T1 (da)
AU (1) AU780413B2 (da)
CA (1) CA2363038C (da)
CZ (1) CZ301266B6 (da)
DE (1) DE60002454T2 (da)
DK (1) DK1171111T3 (da)
ES (1) ES2197867T3 (da)
HU (1) HU228588B1 (da)
IL (2) IL144957A0 (da)
IT (1) IT1305308B1 (da)
PL (1) PL207961B1 (da)
PT (1) PT1171111E (da)
SK (1) SK285565B6 (da)
TR (1) TR200102802T2 (da)
WO (1) WO2000057873A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1399549A (zh) * 1999-09-03 2003-02-26 希格马托健康科学股份公司 超细l－肉碱、其制备方法、含有它的组合物及其使用方法
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
AU2006265280B2 (en) * 2005-07-05 2011-07-14 Lonza Ag Spray-drying process for producing a dry carnitine powder or granulate
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
EP2335495A1 (en) 2009-12-11 2011-06-22 Lonza Ltd. Carnitine granulate and methods for its production
CN102349881B (zh) * 2011-10-26 2013-06-26 东北制药（沈阳）科技发展有限公司 一种左卡尼汀薄膜衣片及其制备方法
CN105695398A (zh) * 2016-04-25 2016-06-22 广西大学 含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
JP7366612B2 (ja) * 2019-07-09 2023-10-23 東和薬品株式会社 レボカルニチンを含有する錠剤
EP4149437A1 (en) 2020-05-15 2023-03-22 Alfasigma S.p.A. Composition comprising methylfolate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
JPS59222412A (ja) * 1983-06-01 1984-12-14 Earth Chem Corp Ltd 心臓疾患治療薬
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1190370B (it) * 1985-06-19 1988-02-16 Zambon Spa Composizione farmaceutica solida per uso orale
JPH03120211A (ja) * 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
JPH0812569A (ja) * 1994-06-24 1996-01-16 Takeda Chem Ind Ltd 塩化カルニチン吸着固形物
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
IT1291126B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) * 1997-04-07 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1290600B1 (it) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato

Also Published As

Publication number Publication date
HUP0200465A2 (en) 2002-06-29
ES2197867T3 (es) 2004-01-16
US20020025984A1 (en) 2002-02-28
PT1171111E (pt) 2003-09-30
CA2363038A1 (en) 2000-10-05
CZ20013078A3 (cs) 2002-02-13
JP2001097353A (ja) 2001-04-10
CN1158072C (zh) 2004-07-21
WO2000057873A3 (en) 2001-04-19
CN1345235A (zh) 2002-04-17
PL350908A1 (en) 2003-02-10
SK11592001A3 (sk) 2001-12-03
KR20010114227A (ko) 2001-12-31
EP1171111B1 (en) 2003-05-02
JP4637367B2 (ja) 2011-02-23
IL144957A (en) 2006-08-01
ATE238784T1 (de) 2003-05-15
ITRM990189A1 (it) 2000-09-26
KR100729848B1 (ko) 2007-06-19
WO2000057873A2 (en) 2000-10-05
SK285565B6 (sk) 2007-03-01
US6485741B2 (en) 2002-11-26
DE60002454D1 (de) 2003-06-05
IL144957A0 (en) 2002-06-30
HU228588B1 (en) 2013-04-29
JP2002540153A (ja) 2002-11-26
PL207961B1 (pl) 2011-02-28
TR200102802T2 (tr) 2002-04-22
EP1171111A2 (en) 2002-01-16
AU3834400A (en) 2000-10-16
DE60002454T2 (de) 2004-03-18
IT1305308B1 (it) 2001-05-04
AU780413B2 (en) 2005-03-17
CA2363038C (en) 2008-10-14
CZ301266B6 (cs) 2009-12-23

Similar Documents

Publication Publication Date Title
CA2199778A1 (en) Extended release formulation of venlafaxine
WO1998004249A3 (de) Tramadol multiple unit formulierungen
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
FI944035A (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
AU2003286994A1 (en) Modified release pharmaceutical composition
EP1435240A3 (en) Solid oral dosage form comprising a combination of methformin and glibenclamide
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
NO880904L (no) Farmasoeytisk tablett, farmasoeytisk granulat og fremgangsmaate for deres fremstilling.
EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
NO841518L (no) Delbare tabletter med forsinket frigjoering av virkestoff, og fremgangsmaate for fremstilling derav
ATE344022T1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
WO1999022724A3 (en) Extended release formulation containing venlafaxin
DK1171111T3 (da) Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
DK616186A (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
DK0755919T3 (da) Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e
ES2189739T3 (es) Composiciones de betahistina de liberacion controlada.
WO1999018941A3 (en) Ih-MODULATORS
AU5139596A (en) Pharmaceutical matrix pellets, tablets and composition for the preparation thereof
GB2295966B (en) Direct compression tablets
CA2239313A1 (en) Solid compound, its preparation and use in medicine
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone